Literature DB >> 19330816

Solution structure of a novel T-cell adhesion inhibitor derived from the fragment of ICAM-1 receptor: cyclo(1,8)-Cys-Pro-Arg-Gly-Gly-Ser-Val-Cys.

Bimo A Tejo1, Teruna J Siahaan.   

Abstract

This study is aimed at elucidating the structure of a novel T-cell adhesion inhibitor, cyclo(1,8)-CPRGGSVC using one- and two-dimensional (2D) (1)H NMR and molecular dynamics (MD) simulation. The peptide is derived from the sequence of its parent peptide cIBR (cyclo(1,12)-PenPRGGSVLVTGC), which is a fragment of intercellular adhesion molecule-1 (ICAM-1). Our previous results show that the cyclo(1,8)-CPRGGSVC peptide binds to the LFA-1 I-domain and inhibits heterotypic T-cell adhesion, presumably by blocking the LFA-1/ICAM-1 interactions. The structure of the peptide was determined using NMR and MD simulation in aqueous solution. Our results indicate that the peptide adopts type-I beta-turn conformation at the Pro2-Arg3-Gly4-Gly5 (PRGG) sequence. The beta-turn structure at the PRGG motif is well conserved in cIBR peptide and ICAM-1 receptor, which suggests the importance of the PRGG motif for the biological activity of cyclo(1,8)-CPRGGSVC peptide. Meanwhile, the Gly5-Ser6-Val7-Cys8-Cys1 (GSVCC) sequence forms a "turn-like" random coil structure that does not belong to any structured motif. Therefore, cyclo(1,8)-CPRGGSVC peptide has only one structured region at the PRGG sequence, which may play an important role in the binding of the peptide to the LFA-1 I-domain. The conserved beta-turn conformation of the PRGG motif in ICAM-1, cIBR, and cyclo(1,8)-CPRGGSVC peptides can potentially be used to design peptidomimetics. (c) 2009 Wiley Periodicals, Inc. Biopolymers 91: 633-641, 2009.This article was originally published online as an accepted preprint. The "Published Online" date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330816      PMCID: PMC2742958          DOI: 10.1002/bip.21192

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  34 in total

Review 1.  What is the importance of the immunological synapse?

Authors:  Daniel M Davis; Michael L Dustin
Journal:  Trends Immunol       Date:  2004-06       Impact factor: 16.687

2.  Synergistic effects of mycophenolate mofetil (MMF, RS-61443) and anti-LFA-1/ICAM-1 monoclonal antibodies on the prolongation of heart allograft survival in rats.

Authors:  K Takazawa; Y Hosoda; H Bashuda; K Seino; H Yagita; T Tamatani; M Miyasaka; K Okumura
Journal:  Transplant Proc       Date:  1996-06       Impact factor: 1.066

3.  Folding of immunogenic peptide fragments of proteins in water solution. I. Sequence requirements for the formation of a reverse turn.

Authors:  H J Dyson; M Rance; R A Houghten; R A Lerner; P E Wright
Journal:  J Mol Biol       Date:  1988-05-05       Impact factor: 5.469

4.  Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit.

Authors:  H Schulze-Koops; P E Lipsky; A F Kavanaugh; L S Davis
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

5.  Calibration of the angular dependence of the amide proton-C alpha proton coupling constants, 3JHN alpha, in a globular protein. Use of 3JHN alpha for identification of helical secondary structure.

Authors:  A Pardi; M Billeter; K Wüthrich
Journal:  J Mol Biol       Date:  1984-12-15       Impact factor: 5.469

6.  A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis.

Authors:  A F Kavanaugh; L S Davis; R I Jain; L A Nichols; S H Norris; P E Lipsky
Journal:  J Rheumatol       Date:  1996-08       Impact factor: 4.666

7.  Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

Authors:  Kenneth B Gordon; Kim A Papp; Tiffani K Hamilton; Patricia A Walicke; Wolfgang Dummer; Nicole Li; Brian W Bresnahan; Alan Menter
Journal:  JAMA       Date:  2003-12-17       Impact factor: 56.272

8.  Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1.

Authors:  M Isobe; H Yagita; K Okumura; A Ihara
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

9.  Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery.

Authors:  Meagan E Anderson; Teruna J Siahaan
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

10.  Relationship between nuclear magnetic resonance chemical shift and protein secondary structure.

Authors:  D S Wishart; B D Sykes; F M Richards
Journal:  J Mol Biol       Date:  1991-11-20       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.